Allogeneic bone marrow mesenchymal stem cell-derived exosomes alleviate human hypoxic AKI-on-a-Chip within a tight treatment window
Open Access
- 10 April 2024
- journal article
- research article
- Published by Springer Nature in Stem Cell Research & Therapy
- Vol. 15 (1) , 1-13
Abstract
Background: Acute hypoxic proximal tubule (PT) injury and subsequent maladaptive repair present high mortality and increased risk of acute kidney injury (AKI) - chronic kidney disease (CKD) transition. Human bone marrow mesenchymal stem cell-derived exosomes (hBMMSC-Exos) as potential cell therapeutics can be translated into clinics if drawbacks on safety and efficacy are clarified. Here, we determined the real-time effective dose and treatment window of allogeneic hBMMSC-Exos, evaluated their performance on the structural and functional integrity of 3D microfluidic acute hypoxic PT injury platform. Methods: hBMMSC-Exos were isolated and characterized. Real-time impedance-based cell proliferation analysis (RTCA) determined the effective dose and treatment window for acute hypoxic PT injury. A 2-lane 3D gravity-driven microfluidic platform was set to mimic PT in vitro. ZO-1, acetylated α-tubulin immunolabelling, and permeability index assessed structural; cell proliferation by WST-1 measured functional integrity of PT. Results: hBMMSC-Exos induced PT proliferation with ED50 of 172,582 µg/ml at the 26th hour. Hypoxia significantly decreased ZO-1, increased permeability index, and decreased cell proliferation rate on 24–48 h in the microfluidic platform. hBMMSC-Exos reinforced polarity by a 1.72-fold increase in ZO-1, restored permeability by 20/45-fold against 20/155 kDa dextran and increased epithelial proliferation 3-fold compared to control. Conclusions: The real-time potency assay and 3D gravity-driven microfluidic acute hypoxic PT injury platform precisely demonstrated the therapeutic performance window of allogeneic hBMMSC-Exos on ischemic AKI based on structural and functional cellular data. The novel standardized, non-invasive two-step system validates the cell-based personalized theragnostic tool in a real-time physiological microenvironment prior to safe and efficient clinical usage in nephrology.Keywords
Funding Information
- Hacettepe University Scientific Research Projects Coordination Unit (TSA-2020-18383)
This publication has 115 references indexed in Scilit:
- Emerging trends in organ-on-a-chip systems for drug screeningActa Pharmaceutica Sinica B, 2023
- Clinical Manufacturing of Human Mesenchymal Stromal Cells using a Potency-Driven ParadigmCurrent Stem Cell Reports, 2022
- Development of a hollow fibre-based renal module for active transport studiesJournal of Artificial Organs, 2021
- Is it Time for Reviewer 3 to Request Human Organ Chip Experiments Instead of Animal Validation Studies?Advanced Science, 2020
- Leptin promotes proliferation of neonatal mouse stem/progenitor spermatogoniaJournal of Assisted Reproduction and Genetics, 2020
- Functional dosing of mesenchymal stromal cell-derived extracellular vesicles for the prevention of acute graft-versus-host-diseaseStem Cells, 2020
- Exosomes from human‐bone‐marrow‐derived mesenchymal stem cells protect against renal ischemia/reperfusion injury via transferring miR‐199a‐3pJournal of Cellular Physiology, 2019
- Translational Assessment of Drug‐Induced Proximal Tubule Injury Using a Kidney Microphysiological SystemCPT: Pharmacometrics & Systems Pharmacology, 2019
- Exosome and Microvesicle-Enriched Fractions Isolated from Mesenchymal Stem Cells by Gradient Separation Showed Different Molecular Signatures and Functions on Renal Tubular Epithelial CellsStem Cell Reviews and Reports, 2017
- Quantitative Analysis of Tissue Distribution of the B16BL6-Derived Exosomes Using a Streptavidin-Lactadherin Fusion Protein and Iodine-125-Labeled Biotin Derivative After Intravenous Injection in MiceJournal of Pharmaceutical Sciences, 2015